A brand new frontline: how artificial intelligence and other innovations are changing the fight against tuberculosis – opinion

March 19, 2026
by Peter Sands, Executive Director

There isn’t any shortage of hype about artificial intelligence in healthcare, but within the fight against tuberculosis (TB), artificial intelligence is already driving a revolution. Portable digital X-ray machines use artificial intelligence to stabilize the image. Analyzing X-ray results using artificial intelligence makes it possible to perform large-scale, high-quality tuberculosis screening even within the poorest and most difficult situations where there’s a shortage of doctors and radiologists. This just isn’t a vision of the longer term, but a reality within the greater than 22 countries where the Global Fund invests in anti-TB programs. Combined with advances in molecular diagnostics and latest battery-powered devices that can dramatically improve the speed and accuracy of diagnosing tuberculosis, we’re seeing a shift in the way in which we discover people affected by this terrible disease that continues to kill greater than every other infectious pathogen.

Currently, almost 2.5 million people develop lively tuberculosis, which isn’t diagnosed, let alone treated. With AI-based screening and less expensive, more accurate and faster diagnostics, we will dramatically reduce these numbers, get people into treatment, save tons of of 1000’s of lives and avoid tens of millions of further infections.

Of course, cool technologies alone should not enough. They must be delivered on a big scale to those that stand to achieve most from them. In the case of tuberculosis, it will likely be the poorest and most marginalized communities which might be most in danger and are those who must be reached. That’s why a rustic like Indonesia, which has one in every of the best rates of tuberculosis on the planet, has completely modified its approach to the disease. Indonesia is leading the way in which in introducing revolutionary screening and diagnosis on the community level. Treatment initiation has been moved from distant hospitals to greater than 460 local “puskesmas,” or primary health centers. In many countries most affected by TB, using private sector clinics and pharmacies is crucial to extend coverage, as they are sometimes the primary point of contact for essentially the most vulnerable communities. Developing viable public-private partnerships against tuberculosis is maybe as essential an innovation because the drugs and devices themselves.

In fact, advances in screening and diagnostics are only one a part of a wave of innovation within the fight against tuberculosis. To understand the potential impact of those innovations, it’s mandatory to briefly explain the fundamental epidemiology of tuberculosis, because even in simplified terms it appears more complex than many other diseases. About 20% of the world’s population has latent tuberculosis, which implies they carry the bacteria but haven’t any symptoms. Although many individuals with latent TB won’t ever develop lively TB, in people whose immune systems are weakened by malnutrition, smoking, one other infectious disease reminiscent of HIV, or a non-communicable disease reminiscent of type 2 diabetes, latent TB can become lively disease. Meanwhile, other individuals who would not have latent TB may simply develop into infected through proximity to individuals with lively TB. The fight against tuberculosis is further complicated by the excellence between drug-resistant tuberculosis, which responds to treatment with relatively inexpensive antibiotics, and drug-resistant tuberculosis, which requires for much longer and dearer treatment.

In addition to innovations in screening and diagnostics, we’re seeing a wave of innovations offering latest ways to deal with each stage of this disease. Better treatments for latent tuberculosis. A variety of preventive tools that reduce the chance of activating latent TB, including a probable TB vaccine which needs to be available around 2029. More effective treatments for each drug-resistant and sensitive TB. In fact, one in every of the best challenges for national TB programs shall be developing the optimal mixture of interventions. Because there won’t ever be enough money for every thing, health ministers might want to determine what combination of tools may have the best impact, given the particular TB epidemic each community faces. Where the vast majority of TB cases are on account of HIV infection, as is the case in most countries in southern and eastern Africa, the answer may lie in investing in HIV prevention and HIV prevention in the primary place. Where extreme poverty and malnutrition are driving lively cases, the response will place greater emphasis on these socio-economic determinants.

This just isn’t about applying a “one size fits all” solution or banking on a silver bullet, but about developing combination strategies that fit each context. The good thing is that we’ll have an increasingly powerful set of tools to work with. The challenge shall be to make sure they’re used as best as possible. Countries themselves – ministries of health, national TB programs, the communities most affected by TB – are best placed to make such decisions. That’s why the Global Fund model gives countries the ability to come to a decision how the cash we offer needs to be prioritized and spent. But along with partners, we also need to supply countries with evidence and technical knowledge to assist them make decisions. Here again, artificial intelligence can play a task.

Global efforts to fight tuberculosis have at all times been underfunded. Thanks to cuts in global healthcare financing, that is much more true now. Displaced people and refugees have at all times been particularly vulnerable to tuberculosis, and the present wave of conflict will only increase these numbers. So on World Tuberculosis Day, it could be all too easy to color a bleak future for our fight against this disease. But it is a alternative, not an inevitability. With decisive leadership – as exemplified by Indonesia – and by intelligently leveraging current and future innovations, we will overcome the challenges and never only maintain the momentum, but in addition speed up the speed of progress within the fight against TB.

This article was first published Forbes.